These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21426013)

  • 1. Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments.
    Vasaitis TS; Njar VC
    Future Med Chem; 2010 Apr; 2(4):667-80. PubMed ID: 21426013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in understanding hormonal therapy resistant prostate cancer.
    Donkena KV; Yuan H; Young CY
    Curr Cancer Drug Targets; 2010 Jun; 10(4):402-10. PubMed ID: 20464780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
    Mellado B; Marin Aguilera M; Pereira MV
    Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway.
    Mellado B; Codony J; Ribal MJ; Visa L; Gascón P
    Clin Transl Oncol; 2009 Jan; 11(1):5-10. PubMed ID: 19155198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
    Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
    Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
    Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
    Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
    Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
    FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The androgen/androgen receptor axis in prostate cancer.
    Bluemn EG; Nelson PS
    Curr Opin Oncol; 2012 May; 24(3):251-7. PubMed ID: 22327838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms mediating androgen receptor reactivation after castration.
    Yuan X; Balk SP
    Urol Oncol; 2009; 27(1):36-41. PubMed ID: 19111796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor as a target in androgen-independent prostate cancer.
    Balk SP
    Urology; 2002 Sep; 60(3 Suppl 1):132-8; discussion 138-9. PubMed ID: 12231070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel hormonal approaches in prostate cancer.
    Friedlander TW; Ryan CJ
    Curr Oncol Rep; 2009 May; 11(3):227-34. PubMed ID: 19336015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independence of HIF1a and androgen signaling pathways in prostate cancer.
    Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
    BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New inhibitors of adrenal androgen synthesis enzymes].
    Mizokami A
    Nihon Rinsho; 2014 Dec; 72(12):2158-63. PubMed ID: 25518351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer.
    Wang Y; Gao W; Li Y; Chow ST; Xie W; Zhang X; Zhou J; Chan FL
    Mol Aspects Med; 2021 Apr; 78():100921. PubMed ID: 33121737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.